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Abstract
Background/Aims
We assessed whether obstructive sleep apnea (OSA) and nocturnal hypoxemia are associ-
ated with severity of liver fibrosis and carotid atherosclerosis in patients with biopsy-proven
NAFLD and low prevalence of morbid obesity. Secondary aim was to explore the associa-
tion of OSA and hypoxemia with NASH and severity of liver pathological changes.
Methods
Consecutive patients (n = 126) with chronically elevated ALT and NAFLD underwent
STOP-BANG questionnaire to estimate OSA risk and ultrasonographic carotid assessment.
In patients accepting to perform cardiorespiratory polygraphy (PG, n = 50), OSA was
defined as an apnea/hypopnea index5. A carotid atherosclerotic plaque was defined as a
focal thickening >1.3 mm.
Results
Prevalence of high OSA risk was similar in patients refusing or accepting PG (76% vs 68%,
p = 0.17). Among those accepting PG, overall OSA prevalence was significantly higher in
patients with F2-F4 fibrosis compared to those without (72% vs 44%; p = 0.04). Significant
fibrosis was independently associated with mean nocturnal oxygen saturation (SaO2)<95%
(OR 3.21, 95%C.I. 1.02–7.34; p = 0.04). Prevalence of OSA tended to be higher in patients
with, than in those without, carotid plaques (64% vs 40%; p = 0.08). Carotid plaques were
independently associated with %time at SaO2<90% >1 (OR 6.30, 95%C.I. 1.02–12.3; p =
0.01).
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Conclusions
In NAFLD patients with chronically elevated ALT at low prevalence of morbid obesity, OSA
was highly prevalent and indexes of SaO2 resulted independently associated with severity
of liver fibrosis and carotid atherosclerosis. These data suggest to consider sleep disor-
dered breathing as a potential additional therapeutic target in severe NAFLD patients.
Introduction
In a short time, the current epidemic of overweight and obesity may lead to an increase in prev-
alence of non-alcoholic fatty liver disease (NAFLD), a major cause of chronic liver disease
worldwide [1–3]. A considerable proportion of patients with NAFLD is at risk of progression
to cirrhosis [2,4], and development of cancer and cardiovascular events [5].
The pathogenesis of NAFLD is multifaceted and incompletely understood. In this complex
landscape, a number of metabolic factors like obesity, insulin resistance (IR) and diabetes [6–8]
have been identified as involved in the pathogenesis and progression of liver fibrosis. Notably,
the same factors have been confirmed as predictors of cardiovascular events among patients
with NAFLD. Besides, new actors in the pathogenesis of liver and cardiovascular damage in
NAFLD are emerging, such as genetic background [9], fructose consumption [10], hyperurice-
mia [11], and vitamin D deficiency [12].
Obstructive sleep apnea (OSA) is characterized by upper airway collapse during sleep, inter-
mittent hypoxia, sympathetic and inflammatory activation, sleep disruption, and increased car-
diovascular risk [13]. A recent large scale Taiwanese population study identified OSA as an
independent predictor of incident liver disease [14], and according to several studies OSA-
associated risk could be particularly high for NAFLD [15–29]. Indeed, studies in humans and
animal models consistently showed that chronic intermittent hypoxia, a common feature of
OSA, is a potent pathogenic trigger not only for cardiovascular, but also for metabolic alter-
ations. Along this line, some studies assessed the potential impact of OSA on liver damage in
patients with NAFLD. Most of these studies on adult patients reported an association between
OSA and ALT levels or histological severity of liver damage, but were performed in morbidly
obese patients [15–23]. Similar data were reported in studies on children with NAFLD [25,26].
The only studies on non-morbidly obese adult NAFLD patients gave inconsistent results. How-
ever, these studies estimated OSA prevalence only by questionnaires [27,28], or they did not
always obtain a histological diagnosis of NAFLD [24,27,29].
Finally, carotid atherosclerosis is frequently associated with OSA [30–32]. NAFLD patients
are at high cardiovascular risk per se [33], but it is unknown whether nocturnal respiratory dis-
orders may independently contribute to vascular damage in this high-risk population.
Having this in mind, the main goal of this study was to assess whether OSA, instrumentally
diagnosed by respiratory polygraphy, and indexes of nocturnal oxygen saturation (SaO2) are
associated with severity of liver fibrosis and carotid atherosclerosis in patients with biopsy-
proven NAFLD and without morbid obesity. Secondary aim was to explore the association of
OSA and indexes of oxygen saturation with nonalcoholic steatohepatitis (NASH), severity of
steatosis, ballooning and lobular inflammation.
Patients and Methods
Patients
The study involved 126 consecutive patients with NAFLD, recruited at the Gastrointestinal &
Liver Unit of Palermo University Hospital, and fulfilling all the inclusion and exclusion criteria
OSA and NAFLD
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detailed below. The main inclusion criterion was a histological diagnosis of NAFLD on a liver
biopsy done less than 6 months before enrollment, showing steatosis (>5% of hepatocytes)
with or without necroinflammation and/or fibrosis including cirrhosis. The pre-biopsy assess-
ment of NAFLD was based on chronically elevated ALT for at least 6 months and alcohol con-
sumption of<20 g/day in the previous year (also confirmed by a questionnaire). Exclusion
criteria were: (1) decompensated cirrhosis (presence of jaundice, ascites or encephalopathy);
(2) hepatocellular carcinoma; (3) liver disease of different or mixed etiology (excessive alcohol
consumption, hepatitis C, hepatitis B, autoimmune liver disease, Wilson’s disease, hemochro-
matosis, α1-antitrypsin deficiency); (4) human immunodeficiency virus infection; (5) previous
treatment with antiviral therapy, immunosuppressive drugs and/or regular use of steatosis-
inducing drugs (steroid, amiodarone, tamoxifen, etc.), as assessed at interview; (6) history of
heart disease (both coronary or cardiac disease); (7) active intravenous drug addiction; (8)
body mass index (BMI) exceeding 45 kg/m2; (9) previous diagnosis of, or assessment for, OSA.
The study was carried out in accordance with the principles of the Helsinki Declaration and
its appendices, and with local and national laws. Approval of the study was obtained from the
AOUP Policlinico Paolo Giaccone of Palermo Review Board and Ethics Committee, and writ-
ten informed consent was obtained from all patients.
Clinical and Laboratory Assessment
Clinical and anthropometric data were collected at the time of liver biopsy. Patients were classi-
fied as normal weight (BMI 18.5–24.9 kg/m2), overweight (BMI 25–29.9), or obese (BMI30).
Waist circumference (WC) was measured at the midpoint between the lower border of the rib
cage and the iliac crest. Visceral obesity was diagnosed whenWC was102 cm in males and
88 cm in females [34]. The diagnosis of arterial hypertension was based on the following cri-
teria: systolic blood pressure 140 mm Hg and/or diastolic blood pressure90 mm Hg (mea-
sured three times within 30 minutes, in the sitting position and using a brachial
sphygmomanometer), or use of blood-pressure-lowering agents. The diagnosis of impaired
glucose tolerance or type 2 diabetes was based on the revised criteria of the American Diabetes
Association, using a value of fasting blood glucose100 to<126, and126 mg/dl, respectively
[35]. In patients with a previous diagnosis of type 2 diabetes, current therapy with insulin or
oral hypoglycemic agents was recorded.
A 12-hour overnight fasting blood sample was drawn at the time of biopsy to determine the
serum levels of ALT, total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides, plasma
glucose, insulin, and platelet count. Insulin resistance (IR) was determined according to the
homeostasis model assessment (HOMA) method [36], as: Insulin resistance (HOMA-IR) =
Fasting insulin (μU/mL) x Fasting glucose (mmol/L)/22.5.
Assessment of Liver Histology
Slides were coded and read by one pathologist, who was unaware of the patient’s identity and
history. A minimum length of 15 mm of biopsy specimen or the presence of at least 10 com-
plete portal tracts was required [37]. Steatosis was assessed as the percentage of hepatocytes
containing fat droplets (minimum 5%), and evaluated as continuous variable. The Kleiner clas-
sification [38] was used to grade steatosis, lobular inflammation, and hepatocellular ballooning,
and to stage fibrosis from 0 to 4. NASH was diagnosed when steatosis, ballooning and lobular
inflammation of any grade were present at the same time.
OSA and NAFLD
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Obstructive Sleep Apnea assessment
Patients filled the validated STOP BANG [39] clinical questionnaire within 3 months from
liver biopsy in order to identify subjects at high risk for OSA. The STOP BANG contains 8
questions: 1. Snoring: Do you snore loudly (loud enough to be heard through closed doors)?;
2. Tired: Do you often feel tired, fatigued, or sleepy during daytime?; 3. Observed: Has anyone
observed you stop breathing during your sleep?; 4. Blood pressure: Do you have or are you
being treated for high blood pressure?; 5. BMI: BMI more than 35 kg/m2?; 6. Age: Age over
50 yrs old?; 7. Neck circumference:>40 cm?; 8. Gender: Male?. A score higher than 2 indicates
high risk for OSA.
Subjective sleepiness was evaluated by the Epworth Sleepiness Scale (ESS), and a score10
was considered indicative of excessive daytime sleepiness [40].
Fifty out of 126 patients accepted to undergo a home nocturnal cardiorespiratory monitor-
ing (Somnea, Compumedics, Abbotsford, Victoria, Australia). The following signals were
recorded: thoracic and abdominal movements by inductance plethysmography, SaO2 by pulse
oximetry, heart rate, nasal airflow by nasal pressure cannulae and pressure transducer, snoring,
and body posture. Sleep period, considered as time between lights off in the evening and lights
on in the morning, was identified based on patients’ diaries and on behaviour of the recorded
signals. Signals recorded in the sleep period were manually analysed [41]. Apneas were scored
when the airflow decreased by at least 90% from baseline for at least 10 seconds and classified
as central, mixed or obstructive depending on occurrence of thoracoabdominal movements
[41]. Hypopneas were scored when airflow decreased by at least 30% for10 seconds and was
associated with a SaO2 fall4%. Apnea/hypopnea index (AHI) was calculated as the average
number of apneas and hypopneas per hour of recording in the sleep period. An AHI5 was
used to diagnose OSA. SaO2 in the sleep period was automatically analysed and the following
parameters were obtained, after manual elimination of possible artifacts: baseline SaO2 during
wakefulness, mean SaO2, time spent with SaO2<90% (T90), lowest nocturnal SaO2 value
[41].
Carotid artery evaluation
Carotid atherosclerosis was evaluated by an expert physician, blinded to the characteristics of
patients, using a high-resolution B-mode ultrasonography equipped with a multifrequency lin-
ear probe.
Bilateral longitudinal projections at the level of the common carotid artery, of the bulb and
of the internal carotid artery were taken. The intima-media thickness (IMT) was measured as
the difference between the first (intima-lumen) and the second (media-adventitia) interface on
the far wall of the common carotid arteries in a section free of plaques beginning 10 mm below
their bifurcations and including the bifurcations for 10 mm. For each subject, three measure-
ments on both sides were performed, i.e., the anterior, lateral, and posterior projection of the
near and far wall. Maximum (outside the plaque) values of IMT were considered, and edge
detection was performed manually. IMT measurements from the left and right side were aver-
aged. A plaque was defined as a focal thickening>1.3 mm at one or more levels of carotid
arteries or of their bifurcation [42].
Statistics
Continuous variables were summarized as mean ± standard deviation or median (95% C.I.),
and categorical variables as percentage. T-test or chi-square test were used when appropriate.
Multiple logistic regression models were used to assess the factors independently associated
with significant liver fibrosis and carotid plaques (main aims). Multiple logistic and ordinal
OSA and NAFLD
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regression models were used to assess the factors associated with NASH, severity of steatosis,
ballooning and lobular inflammation. For SaO2 variables, the median was used as a cut-off
value. Variables included in multivariate models were chosen as potential confounders, based
on their significance at univariate analyses (p<0.10) and/or their biological plausibility.
High risk for OSA, age, gender and hypertension, as well as metabolic syndrome and its
components were not included in the same models due to co-linearity.
Regression analyses were performed using SAS [43].
Results
Patients
We included 126 consecutive patients with NAFLD who responded to the STOP-BANG ques-
tionnaire, and underwent carotid ultrasonography and liver biopsy. At liver biopsy, approxi-
mately one patient in two had fibrosis 2 by Kleiner score, while two in three had diagnosis of
NASH.
Seventy-six patients (60%) refused the sleep study, while 50 patients underwent cardiorespi-
ratory polygraphy. S1 Table shows the comparison between NAFLD patients according to
acceptance of the sleep study. The patients who accepted had a higher prevalence of metabolic
comorbidities like obesity, hypertension and diabetes, even if prevalence of high risk for OSA
assessed by STOP-BANG questionnaire was similar in the two groups, as well as the degree of
liver damage in terms of steatosis, lobular inflammation, ballooning, NASH and fibrosis.
In patients who underwent sleep studies, mean age was 53 years, and there was a slight male
predominance (58%). Most patients (60%) showed visceral obesity, 50% were hypertensive,
and 40% were diabetic. Mean values for total, HDL-cholesterol, and triglycerides were within
the normal range, whereas mean HOMA value was elevated (4.4 ± 2.4).
Characteristics of patients with Obstructive Sleep Apnea (AHI5)
Demographic, clinical and metabolic characteristics of patient at low (n = 39) or high (n = 87)
risk of OSA according to the STOP-BANG questionnaire are reported in S2 Table. Among
patients who accepted the sleep study, an AHI5 was observed in 50% of the subjects, even if
an AHI>30 (i.e. severe OSA) was found only in 20% of cases. Notably, all patients with AHI5
were in the high-risk group according to the STOP-BANG questionnaire, but the questionnaire
correctly identified only 65% of the patients with OSA. Hence, sensitivity, specificity, positive
predictive value and negative predictive value of STOP-BANG in diagnosing OSA in patients
with NAFLD were 100%, 48%, 65% and 100%, respectively.
Characteristics of patients according to the presence or absence of AHI5 are reported in
Table 1. As expected, patients with AHI5 were older and had a higher prevalence of obesity,
hypertension and diabetes compared to those without OSA (p<0.05 for all). When considering
oxygen saturation parameters, patients with AHI5 had worse mean SaO2 and T90 (p<0.01
for both). Notably, no differences in subjective sleepiness were observed between patients with
and without OSA (Table 1) or between patients at low or high risk for OSA assessed by the
Epworth questionnaire (S2 Table).
The severity of liver damage is associated with high risk for OSA and
lower oxygen saturation
In the entire cohort of 126 patients the prevalence of F2-F4 fibrosis was higher in patients at
high risk compared to those without high risk for OSA (80.6% vs 57.8%, p = 0.006), this associ-
ation remaining marginally significant after adjusting for confounders (O.R. 2.25, 95%C.I.
OSA and NAFLD
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0.97–5.22; p = 0.05) (Table 2). Similar results were obtained when replacing WC and HOMA
with metabolic syndrome in the model.
When considering patients who underwent sleep studies, subjects with F2-F4 fibrosis, as
compared to their counterparts with F0-F1 fibrosis, showed a significantly higher prevalence of
Table 1. Baseline Demographic, Laboratory, Metabolic, and Histological Features of 50 Italian Patients with biopsy-proven Non-alcoholic Fatty
Liver Disease according to presence or absence of obstructive sleep apnea.
Variable AHI<5 AHI5 P value
n = 25 n = 25
Age–years 49.6 ± 11.7 56.1 ± 9.1 0.03
Male Gender—% of subjects 56 60 0.77
BMI—kg/m2 29.0 ± 3.6 33.5 ± 4.7 <0.001
BMI<25 kg/m2 - % of subjects 12.0 4.0
BMI25-<30 kg/m2- % of subjects 48.0 12.0
BMI30-<35 kg/m2- % of subjects 32.0 40.0
BMI35-<40 kg/m2- % of subjects 8.0 32.0
BMI40 kg/m2- % of subjects 0 12.0 0.005
Waist Circumference–cm 101.6 ± 9.2 111.7 ± 11.4 0.001
Visceral Obesity—% of subjects 68 92 0.03
Alanine Aminotransferase–IU/ml 63.6 ± 34.5 66.5 ± 33.4 0.76
Blood glucose–mg/dl 97.0 ± 20.7 119.1 ± 38.8 0.01
Insulin–IU 17.1 ± 9.4 19.6 ± 11.6 0.49
HOMA 4.07 ± 2.17 4.78 ± 2.75 0.32
Type 2 Diabetes- % of subjects 20 60 0.004
Arterial Hypertension- % of subjects 20 80 <0.001
Metabolic Syndrome—% of subjects 20 24 0.73
Smoking—% of subjects 20 24 0.39
HDL Cholesterol–mg/dl 51.9 ± 12.1 56.8 ± 30.8 0.46
LDL Cholesterol–mg/dl 128.3 ± 33.0 107.0 ± 39.4 0.04
Triglycerides–mg/dl 124.3 ± 45.1 136.5 ± 86.6 0.53
Intima Media Thickness—mm 0.82 ± 0.18 0.83 ± 0.14 0.73
Carotid Plaques—% of subjects 40 64 0.08
AHI–no/hour 2 (0–4.8) 11 (5–52) <0.001
Basal SaO2 - % 96.4 ± 0.9 95.6 ± 1.5 0.01
Mean Sa02 - % 94.8 ± 1.3 92.9 ± 2.2 0.001
Mean Sa02 <95%—% of subjects 28 84 <0.001
T90 - % 3.1 (0.3–6.3) 13.3 (6.5–42.7) <0.001
T90 >1%—% of subjects 16 56 0.003
ESS score 5.5 ± 3.1 7.0 ± 3.3 0.11
ESS score 10 (%)—% of subjects 16 16 1.00
Histology
Lobular inﬂammation 2–3 - % of subjects 44 43.4 0.97
Steatosis grade 3 (>66%)—% of subjects 20 34.7 0.25
Ballooning—% of subjects 64 91 0.02
NASH—% of subjects 60 88 0.02
Fibrosis Stage 2–4 - % of subjects 44 72 0.04
Abbreviations: IU, international units; HOMA, homeostasis model assessment; HDL, high density lipoprotein; LDL, low density lipoprotein; AHI, apnea-
hypopnea index; SaO2, oxygen saturation; T90%, percentage of total sleep time spent with SaO2<90; ESS, Epworth Sleepiness Scale. Data are given as
mean ± standard deviation, or as median (95% C.I.), or as %.
doi:10.1371/journal.pone.0142210.t001
OSA and NAFLD
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AHI5 (72% vs 44%; p = 0.04), as well as of mean SaO2<95% (median value in the whole
group) (69% vs 38%; p = 0.03), but no significant difference in the prevalence of T90>>1%
(44% vs 24%; p = 0.12). Of note, after correction for confounders, the association between sig-
nificant fibrosis and AHI5 was lost (OR 1.60, 95%C.I. 0.33–7.66; p = 0.55), while the associa-
tion with mean SaO2<95% was maintained (OR 3.21, 95%C.I. 1.02–7.34; p = 0.04) (Table 3).
Fig 1 shows the prevalence of significant fibrosis according to mean SaO2<<95%.
When considering the entire cohort of 126 patients, after adjusting for WC and HOMA, an
independent association was observed between high risk for OSA and both NASH (p = 0.02)
and ballooning (p = 0.03) (Fig 2). Similarly, in the subgroup of 50 patients who underwent
sleep studies a significantly higher prevalence of NASH (88% vs 60%, p = 0.02) and ballooning
(91% vs 64%; p = 0.02) was observed in those with AHI>5, but such associations became
nonsignificant after adjusting for confounders (data not shown).
Carotid plaques are associated with high risk for OSA and lower oxygen
saturation
In the entire cohort of 126 patients the prevalence of carotid plaques was higher in patients at
high risk compared to those at low risk for OSA (51.2% vs 24.3%, p = 0.006), this association
being maintained after adjusting for confounders (O.R. 3.17, 95%C.I. 1.26–7.94; p = 0.01)
(Table 4). Similar results were obtained when replacing WC, HOMA, hypertension and LDL-
cholesterol with metabolic syndrome in the model. When IMT was assessed as a continuous
variable, high risk for OSA and higher LDL-cholesterol resulted independently associated with
higher IMT (p = 0.005) after adjustments for WC, HOMA, and smoking (p = 0.03).
Among patients who underwent sleep studies, subjects with carotid plaques showed nonsig-
nificant trends toward higher prevalence of OSA (64% vs 40%; p = 0.08) and of mean SaO2
Table 2. Univariate andmultivariate analyses of factors associated with F2-F4 Fibrosis in 126 patients
with nonalcoholic fatty liver disease who were administered STOP-BANG.
Variable Unadjusted Model Adjusted Model
Waist Circumference 1.05 (1.01–1.09) 0.003 1.03 (0.99–1.07) 0.07
HOMA 1.38 (1.12–1.70) 0.002 1.23 (0.99–1.54) 0.06
High Risk for OSA 3.04 (1.36–6.78) 0.007 2.25 (0.97–5.22) 0.05
Abbreviations: HOMA, homeostasis model assessment; OSA, obstructive sleep apnea; AHI, apnea-
hypopnea index; SaO2, oxygen saturation; T90, percentage of total sleep time spent with SaO2<90%.
doi:10.1371/journal.pone.0142210.t002
Table 3. Univariate andmultivariate analyses of factors associated with F2-F4 Fibrosis in 50 patients with nonalcoholic fatty liver disease who
underwent sleep study.
Variable Unadjusted Model Adjusted Model Adjusted Model Adjusted Model
Male gender 1.32 (0.42–4.14) 0.63 1.05 (0.23–4.78) 0.94 0.82 (0.19–3.54) 0.79 0.91 (0.21–3.93) 0.89
Age 1.12 (1.04–1.20) 0.001 1.14 (1.04–1.25) 0.005 1.13 (1.03–1.23) 0.005 1.13 (1.03–1.23) 0.004
Waist Circumeference 1.03 (0.98–1.09) 0.15 0.98 (0.91–1.06) 0.71 0.99 (0.92–1.07) 0.97 0.99 (0.92–1.07) 0.92
HOMA 1.33 (1.00–1.77) 0.04 1.49 (1.01–2.20) 0.04 1.39 (0.99–1.95) 0.05 1.41 (1.01–2.07) 0.04
AHI 5 3.27 (1.00–10.6) 0.04 1.60 (0.33–7.66) 0.55
Mean Sa02 <95%* 3.61 (1.10–11.7) 0.01 3.21 (1.02–7.34) 0.04
T90 >1% 2.83 (0.87–9.13) 0.08 2.43 (0.53–11.2) 0.25
Abbreviations: HOMA, homeostasis model assessment; OSA, obstructive sleep apnea; AHI, apnea-hypopnea index; SaO2, oxygen saturation; T90,
percentage of total sleep time spent with SaO2<90%.
doi:10.1371/journal.pone.0142210.t003
OSA and NAFLD
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<95% (68% vs 44%; p = 0.09), and a significantly higher occurrence of T90>1% (52% vs 17%;
p = 0.01). After correction for confounders, the association between carotid plaques and both
AHI5 (OR 1.14, 95%C.I. 0.18–6.99; p = 0.88) and mean SaO2<<95% (OR 0.95, 95%C.I.
0.16–5.67; p = 0.96) became nonsignificant, while the association with T90>1% remained sig-
nificant (OR 6.30, 95%C.I. 1.02–12.3; p = 0.01) (Table 5). Fig 3 shows the prevalence of carotid
plaques according to T90>1%. However, when IMT was analysed as a continuous variable, no
association was found with AHI or SaO2 indexes (data not shown).
Discussion
In a western cohort of biopsy-proven NAFLD patients with a low prevalence of morbid obesity
and a high prevalence of significant liver fibrosis, 69% of patients were at high risk for OSA
according to the STOP-BANG questionnaire. Among patients undergoing a nocturnal respiratory
polygraphy, an AHI5 at was present in half of the cases, and some indexes of oxygen saturation
resulted independently associated with both the severity of liver fibrosis and carotid atherosclero-
sis. Of note, these associations were maintained after correction for both hepatic and cardiometa-
bolic confounders despite potentially low statistical power due to the small sample size.
In the last years, several studies have reported a strong link between OSA and cardiometa-
bolic alterations, as well as between OSA and direct, i.e., hepatic histology—or indirect, i.e.,
ALT or GGT levels, markers of liver damage in NAFLD patients [13–29]. In our cohort we
observed an independent association between severity of liver damage, namely significant
fibrosis, NASH and ballooning, and high risk for OSA assessed by the STOP-BANG question-
naire. Our results agree with those reported by Pulixi and colleagues [28] who studied a similar
cohort of biopsy-proven adult NAFLD patients without morbid obesity, but used a different
tool for OSA screening, i.e. the Berlin questionnaire. Instead, in a similar clinical setting no
association between high risk for OSA and liver damage was reported by Singh and colleagues
[27]; however, in that study liver damage was estimated based on serum ALT, which is a less
reliable surrogate of liver damage [44].
Fig 1. Prevalence of F2-F4 liver fibrosis among the 50 patients who underwent a sleep study during
which they showed a nocturnal mean oxygen saturation < <or95%.
doi:10.1371/journal.pone.0142210.g001
OSA and NAFLD
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In our study, prevalence of AHI5 was 50% according to cardiorespiratory polygraphy. To
the best of our knowledge, this is the first study showing an independent association between
nocturnal oxygen saturation values and significant liver fibrosis in adult patients with biopsy-
proven, severe NAFLD at low prevalence of morbid obesity. Similar observations were previ-
ously obtained in cohorts of bariatric patients [15–22], who differ for anthropometric and
Fig 2. Association between NASH (A), severity of steatosis (B), severity of ballooning (C) and severity of lobular inflammation (D) with high risk
OSA assessed by the STOP-BANG questionnaire. P values are adjusted for waist circumference and HOMA.
doi:10.1371/journal.pone.0142210.g002
Table 4. Univariate andmultivariate analyses of factors associated with carotid plaques in 126 patients with nonalcoholic fatty liver disease who
were administered STOP-BANG.
Variable Unadjusted Model Adjusted Model
Waist Circumeference 1.00 (0.97–1.03) 0.59 0.98 (0.95–1.02) 0.56
HOMA 1.19 (0.99–1.44) 0.06 1.15 (0.92–1.45) 0.20
LDL cholesterol 1.00 (0.99–1.01) 0.19 1.00 (0.99–1.01) 0.18
Smoking 1.74 (0.74–4.09) 0.19 1.73 (0.69–4.28) 0.23
High Risk OSA 3.26 (1.37–7.74) 0.007 3.17 (1.26–7.94) 0.01
Abbreviations: HOMA, homeostasis model assessment; LDL, low density lipoprotein; OSA, obstructive sleep apnea; AHI, apnea-hypopnea index; SaO2,
oxygen saturation; T90, percentage of total sleep time spent with SaO2<90%.
doi:10.1371/journal.pone.0142210.t004
OSA and NAFLD
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perhaps genetic features from “normal” NAFLD, and in two studies on children with NAFLD
[25,26].
NAFLD patients are known to be at high risk of vascular dysfunction and carotid athero-
sclerosis due to the high prevalence of metabolic comorbidities and to their pro-atherogenic
and pro-coagulant imbalance [33]. In our sample of NAFLD patients we found that a high risk
for OSA as well as a T90>1% were independently associated with subclinical carotid athero-
sclerosis evaluated as IMT and carotid plaques. Therefore, our data suggest that OSA could
contribute to atherogenic lesions in NAFLD patients, possibly through the effects of nocturnal
exposure to hypoxia. Many studies have reported a pathogenetic link between OSA and athero-
sclerosis, albeit with some disagreement [13]. Specifically, studies performed in different
Table 5. Univariate andmultivariate analyses of factors associated with carotid plaques in 50 patients with nonalcoholic fatty liver disease who
underwent sleep study.
Variable Unadjusted Model Adjusted Model Adjusted Model Adjusted Model
Male gender 1.73 (0.54–5.53) 0.35 1.06 (0.23–4.95) 0.93 0.81 (0.18–3.57) 0.78 0.81 (0.18–3.60) 0.78
Age 1.13 (1.04–1.22) 0.002 1.12 (1.02–1.23) 0.01 1.13 (1.03–1.24) 0.008 1.13 (1.03–1.24) 0.008
Waist Circumeference 1.03 (0.98–1.09) 0.18 1.03 (0.95–1.11) 0.40 1.04 (0.96–1.12) 0.32 1.04 (0.96–1.12) 0.31
HOMA 1.13 (1.88–1.44) 0.33 1.17 (0.84–1.63) 0.33 1.08 (0.79–1.45) 0.61 1.08 (0.80–1.46) 0.60
LDL cholesterol 1.00 (0.99–1.02) 0.39 1.02 (0.99–1.04) 0.07 1.01 (0.99–1.04) 0.10 1.01 (0.99–1.04) 0.10
Arterial Hypertension 2.81 (0.87–9.09) 0.08 0.73 (0.12–4.42) 0.73 1.20 (0.18–7.86) 0.84 1.28 (0.24–6.76) 0.76
Smoking 1.13 (0.29–4.38) 0.85 0.72 (0.09–5.41) 0.75 1.58 (0.27–9.15) 0.60 1.58 (0.25–9.79) 0.62
AHI 5 2.81 (0.87–9.09) 0.08 1.14 (0.18–6.99) 0.88
Mean Sa02 <95% 2.76 (0.85–8.96) 0.09 0.95 (0.16–5.67) 0.96
T90 >1% 4.58 (1.38–15.1) 0.01 6.30 (1.02–12.3) 0.01
Abbreviations: HOMA, homeostasis model assessment; LDL, low density lipoprotein; OSA, obstructive sleep apnea; AHI, apnea-hypopnea index; SaO2,
oxygen saturation; T90, percentage of total sleep time spent with SaO2<90%.
doi:10.1371/journal.pone.0142210.t005
Fig 3. Prevalence of carotid plaques among the 50 patients who underwent a sleep study during
which they spent <<1% or1% of time with oxygen saturation90%.
doi:10.1371/journal.pone.0142210.g003
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settings like general population or patients at risk for OSA highlighted that OSA and/or oxygen
saturation indexes are associated with IMT and/or carotid plaques [30–32]. Our study however
is the first one reporting these associations in a setting of NAFLD patients at low prevalence of
morbid obesity.
From a clinical point of view, our study suggests that occurrence of sleep disordered breath-
ing in NAFLD patients should be assessed by following a 2-step approach: first, administration
of the STOP-BANG questionnaire and then, in patients positive to the questionnaire, a noctur-
nal sleep study. In fact, the questionnaire proved highly sensitive but poorly specific in our
patients, so that occurrence of OSA could be overestimated by using only that tool. Moreover,
the symptom of daytime sleepiness was rarely reported by NAFLD patients. The identification
of OSA in patients with NAFLD could be followed by OSA treatment, with benefits on meta-
bolic and perhaps liver alterations. A recent longitudinal study from our group suggested that
OSA treatment by continuous positive airway pressure might be associated with decreased
liver steatosis [45].
Our study is merely observational and was not designed to explore mechanisms for the asso-
ciation of OSA and either liver fibrosis or atherosclerosis in NAFLD patients. However, accord-
ing to recent evidence, we may put forward a few hypotheses to be further tested in
experimental studies. Intermittent hypoxia, in addition to systemic inflammation, could pro-
mote atherosclerosis and liver damage as observed in murine models of NAFLD [46–49], and
liver profibrogenic infiltrate as expressed by increased intrahepatic leukocytes and activated
macrophages/Kupffer cells in human NAFLD [24,25]. In addition, the interplay between
decreased oxygen saturation, liver damage, vascular alterations and metabolic dysfunction can
stem from a common pathway that hypoxia and insulin resistance can activate and amplify.
Experimental studies showed that both insulin resistance and intermittent hypoxia are able to
stimulate the carotid bodies, i.e. peripheral chemoreceptors that classically respond to hypoxia
causing hyperventilation through an increase in the carotid sinus nerve activity In addition, the
carotid sinus nerve discharge increases the activity of the sympathoadrenal system, and ampli-
fies mechanisms leading to insulin resistance and its systemic complications, including liver
and vascular damage [50,51]. However, our data, while suggesting a possible role for nocturnal
hypoxia in such alterations, do not indicate a specific and/or exclusive role of intermittent hyp-
oxia. Both mean SaO2 and T90 reflect the nocturnal hypoxic load, rather than the intermittent
cycles of hypoxia/reoxygenation associated with respiratory events. Nobili and coworkers also
found that T90 was the strongest predictor of NASH severity and fibrosis stage in pediatric
NAFLD (25). Finally, as demonstrated in children with NAFLD, OSA could induce liver dam-
age by increasing intestinal permeability and endotoxemia, that in turn activate Kupffer and
hepatic stellate cells, and by expanding adiponectin-deficient hepatic progenitor cells, key fea-
tures of steatohepatitis and fibrosis [52]. Further studies are needed to better understand the
role of nocturnal hypoxia as a marker of increased risk in NAFLD, and to assess the potential
usefulness of nocturnal pulse oximetry studies in patients affected by this disease.
The study has both strengths and limitations. The main strength is the availability of a
homogeneous cohort of biopsy-proven NAFLD patients, with a low prevalence of morbid obe-
sity, fully studied for sleep disordered breathing, as well as for metabolic, liver and carotid alter-
ations. However, results were obtained in a cohort of Italian patients with elevated ALT levels
and a high prevalence of NASH and F2-F4 fibrosis enrolled at a tertiary care center, and may
not be readily applicable to patients with NAFLD from the general population. The cross-sec-
tional nature of our study does not prove a causal link between OSA and liver or vascular dam-
age. A further methodological issue is the relative small sample size. Besides, more than 50% of
the studied population refused the sleep study. Nevertheless, prevalence of high risk for OSA,
based on the results of the questionnaire, was similar in patients with and without sleep studies,
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even if the former ones had a higher prevalence of metabolic comorbidities. Although hypox-
emia could have been also related to a cardiac cause, the lack of cardiological symptoms, the
exclusion of patients with a previous history of cardiovascular disorders, and the fact that a
high proportion of these patients underwent echocardiography without evidence of severe car-
diac alterations [53] make this possibility unlikely. Finally, OSA was not diagnosed by full poly-
somnography, but our choice to use cardiorespiratory polygraphy was warranted by the
widespread and increasing acceptance of the reliability of this diagnostic tool [54].
In conclusion, in a cohort of NAFLD patients enrolled in a tertiary care center and showing
a low prevalence of morbid obesity, AHI5 was highly prevalent. Our data suggest that indexes
of oxygen saturation were associated with severity of liver damage and of carotid atherosclero-
sis risk. These data, if further validated, suggest that occurrence of sleep disordered breathing
should be investigated in NAFLD patients, since OSA is a treatable condition and may repre-
sent a potential additional therapeutic target for NAFLD.
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